• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » CROs Simbec Research, Orion merge

CROs Simbec Research, Orion merge

June 23, 2014
CenterWatch Staff

Simbec Research, a specialist CRO in early stage clinical development, and Orion, a specialist CRO in late stage clinical development, have merged. Following closing, the group will be known as Simbec-Orion Group, and both the Simbec and Orion brands will continue in their respective fields.

The merger has created a full-service international CRO with capabilities in both early stage and late stage clinical development experience in oncology and rare and orphan diseases. The group, with combined revenues of approximately $42.5 million, employs 250 staff and has operations across Europe, Australia and the U.S., together with capabilities in multiple other territories. Simbec-Orion will maintain its headquarters in the U.K. in South Wales.

Simbec-Orion will offer its current 65 large and mid-cap pharmaceutical and biotech clients a complete service offering from first-in-human exploratory clinical pharmacology studies, through phase II and phase III studies. Currently, the group has approximately 90 clinical trials running. In addition, the group offers phase IV post-authorization studies for marketing, observational and safety studies (PASS). These are complemented by in-house dedicated central laboratory facilities (bioanalytics and pathology) to interpret samples from all clinical trials conducted in-house, as well as providing support services to its clients for additional samples and to smaller CROs without an in-house capability.

Simbec-Orion can offer comprehensive services in regulatory affairs, pharmacovigilance (both clinical and post-marketing), medical affairs and central pharmacy, all serviced by an in-house capability. The merger was completed through the provision of $21.3 million of funds raised from the Welsh Arthurian Life Sciences Fund and HSBC Bank West and Wales corporate team, which provided debt finance in this leveraged transaction.

It is the board's and the funders' intention to pursue a buy and build strategy to invest in existing operations, to drive organic growth and to rapidly pursue further acquisitions to expand its geographic reach, service offering and therapeutic areas of clinical excellence.

Ronald Openshaw, CEO, from Lucia Capital, and Dr. Fabrice Chartier, new chief operating officer, previously director of scientific affairs of Orion, will join the board of director. The board is completed by its existing directors professor Trevor Jones, non-executive chairman; Howard Jenkins, managing director; Dr. Trevor Tanner, chief scientific officer; and professor Sir Christopher Evans, non-executive director. Dr. Alan Irvine, CEO Orion Clinical Services, has agreed to assume the role of group chief medical officer.

Upcoming Events

  • 24May

    Powering an Effective Oversight Strategy with Clinical and Operational Insights

  • 25May

    2022 WCG Avoca Quality & Innovation Summit: Own the Future

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 16Oct

    WCG MAGI's Clinical Research Hybrid Conference - 2022 West

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Protocol-360x240.png

    Avoid Deviations by Making Protocol Review a Team Effort

  • SelectionProcess-360x240.png

    Give Us a Voice: Sites Clamor for a Say on Vendor Selection

  • Convince-360x240.png

    Use Data and Details to Convince Site Leadership to Add Staff

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing